All data are based on the daily closing price as of December 3, 2024
l
Lumosa Therapeutics
6535.TWO
8.99 USD
-0.98
-9.83%
Overview
Last close
8.99 usd
Market cap
1.48B usd
52 week high
12.06 usd
52 week low
1.81 usd
Target price
7.5 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
1123.2059
Price/Book Value
51.5647
Enterprise Value
1.81B usd
EV/Revenue
1559.7421
EV/EBITDA
N/A
Key financials
Revenue TTM
1.47M usd
Gross Profit TTM
N/A usd
EBITDA TTM
-10.30M usd
Earnings per Share
-0.07 usd
Dividend
N/A usd
Total assets
1.60B usd
Net debt
-279.44M usd
About
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.